Cargando…

A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function

BACKGROUND: The Holt–Oram syndrome (HOS) is an autosomal dominant disorder affecting 1/100.000 live births. It is defined by upper limb anomalies and congenital heart defects with variable severity. We describe a dramatic phenotype of a male, 15‐month‐old patient being investigated for strict diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Dreßen, Martina, Lahm, Harald, Lahm, Armin, Wolf, Klaudia, Doppler, Stefanie, Deutsch, Marcus‐André, Cleuziou, Julie, Pabst von Ohain, Jelena, Schön, Patric, Ewert, Peter, Malcic, Ivan, Lange, Rüdiger, Krane, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023941/
https://www.ncbi.nlm.nih.gov/pubmed/27652283
http://dx.doi.org/10.1002/mgg3.234
_version_ 1782453715754549248
author Dreßen, Martina
Lahm, Harald
Lahm, Armin
Wolf, Klaudia
Doppler, Stefanie
Deutsch, Marcus‐André
Cleuziou, Julie
Pabst von Ohain, Jelena
Schön, Patric
Ewert, Peter
Malcic, Ivan
Lange, Rüdiger
Krane, Markus
author_facet Dreßen, Martina
Lahm, Harald
Lahm, Armin
Wolf, Klaudia
Doppler, Stefanie
Deutsch, Marcus‐André
Cleuziou, Julie
Pabst von Ohain, Jelena
Schön, Patric
Ewert, Peter
Malcic, Ivan
Lange, Rüdiger
Krane, Markus
author_sort Dreßen, Martina
collection PubMed
description BACKGROUND: The Holt–Oram syndrome (HOS) is an autosomal dominant disorder affecting 1/100.000 live births. It is defined by upper limb anomalies and congenital heart defects with variable severity. We describe a dramatic phenotype of a male, 15‐month‐old patient being investigated for strict diagnostic criteria of HOS. METHODS AND RESULTS: Genetic analysis revealed a so far unpublished TBX5 mutation, which occurs de novo in the patient with healthy parents. TBX5 belongs to the large family of T‐box transcription factors playing major roles in morphogenesis and cell‐type specification. The mutation located in the DNA‐binding domain at position 920 (C→A) leads to an amino acid change at position 85 (proline → threonine). Three‐dimensional analysis of the protein structure predicted a cis to trans change in the respective peptide bond, thereby probably provoking major conformational and functional alterations of the protein. The p.Pro85Thr mutation showed a dramatically reduced activation (97%) of the NPPA promoter in luciferase assays and failed to induce NPPA expression in HEK 293 cells compared to wild‐type TBX5 protein. The mutation did not interfere with the nuclear localization of the protein. CONCLUSION: These results suggest that the dramatic functional alteration of the p.Pro85Thr mutation leads to the distinctive phenotype of the patient.
format Online
Article
Text
id pubmed-5023941
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50239412016-09-20 A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function Dreßen, Martina Lahm, Harald Lahm, Armin Wolf, Klaudia Doppler, Stefanie Deutsch, Marcus‐André Cleuziou, Julie Pabst von Ohain, Jelena Schön, Patric Ewert, Peter Malcic, Ivan Lange, Rüdiger Krane, Markus Mol Genet Genomic Med Original Articles BACKGROUND: The Holt–Oram syndrome (HOS) is an autosomal dominant disorder affecting 1/100.000 live births. It is defined by upper limb anomalies and congenital heart defects with variable severity. We describe a dramatic phenotype of a male, 15‐month‐old patient being investigated for strict diagnostic criteria of HOS. METHODS AND RESULTS: Genetic analysis revealed a so far unpublished TBX5 mutation, which occurs de novo in the patient with healthy parents. TBX5 belongs to the large family of T‐box transcription factors playing major roles in morphogenesis and cell‐type specification. The mutation located in the DNA‐binding domain at position 920 (C→A) leads to an amino acid change at position 85 (proline → threonine). Three‐dimensional analysis of the protein structure predicted a cis to trans change in the respective peptide bond, thereby probably provoking major conformational and functional alterations of the protein. The p.Pro85Thr mutation showed a dramatically reduced activation (97%) of the NPPA promoter in luciferase assays and failed to induce NPPA expression in HEK 293 cells compared to wild‐type TBX5 protein. The mutation did not interfere with the nuclear localization of the protein. CONCLUSION: These results suggest that the dramatic functional alteration of the p.Pro85Thr mutation leads to the distinctive phenotype of the patient. John Wiley and Sons Inc. 2016-07-14 /pmc/articles/PMC5023941/ /pubmed/27652283 http://dx.doi.org/10.1002/mgg3.234 Text en © 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Dreßen, Martina
Lahm, Harald
Lahm, Armin
Wolf, Klaudia
Doppler, Stefanie
Deutsch, Marcus‐André
Cleuziou, Julie
Pabst von Ohain, Jelena
Schön, Patric
Ewert, Peter
Malcic, Ivan
Lange, Rüdiger
Krane, Markus
A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function
title A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function
title_full A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function
title_fullStr A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function
title_full_unstemmed A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function
title_short A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function
title_sort novel de novo tbx5 mutation in a patient with holt–oram syndrome leading to a dramatically reduced biological function
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023941/
https://www.ncbi.nlm.nih.gov/pubmed/27652283
http://dx.doi.org/10.1002/mgg3.234
work_keys_str_mv AT dreßenmartina anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT lahmharald anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT lahmarmin anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT wolfklaudia anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT dopplerstefanie anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT deutschmarcusandre anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT cleuzioujulie anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT pabstvonohainjelena anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT schonpatric anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT ewertpeter anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT malcicivan anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT langerudiger anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT kranemarkus anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT dreßenmartina noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT lahmharald noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT lahmarmin noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT wolfklaudia noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT dopplerstefanie noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT deutschmarcusandre noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT cleuzioujulie noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT pabstvonohainjelena noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT schonpatric noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT ewertpeter noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT malcicivan noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT langerudiger noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction
AT kranemarkus noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction